Business Context and Reporting Period
Trisalus Life Sciences, Inc. (TLSI) is an oncology-focused medical technology company reporting for the fiscal year ended December 31, 2024. The company operates a dual-platform strategy: commercializing the TriNav Infusion System, a Pressure-Enabled Drug Delivery (PEDD) device for liver and pancreatic tumors, and developing nelitolimod, an investigational immunotherapeutic. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $29.4 million | $18.5 million |
| Gross Profit | $25.3 million | $15.9 million |
| Gross Margin | 86.1% | 85.9% |
| Net Loss (Available to Common) | $(30.0) million | $(59.4) million |
| Net Loss (Attributable to Common) | $(33.2) million | $(63.6) million |
| Cash and Cash Equivalents (Year End) | $8.5 million | $11.8 million |
| Operating Cash Flow | $(40.8) million | $(50.6) million |
| Long-Term Debt (Net) | $22.1 million | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 59.0% year-over-year, driven by higher sales volumes of the TriNav device.
- Expense Management: Research and Development (R&D) expenses decreased 40.7% to $17.7 million due to the completion of certain clinical studies. Conversely, Sales and Marketing expenses increased 51.7% to $25.8 million to support commercial expansion.
- Debt Financing: The company entered into a $50.0 million credit agreement with OrbiMed in April 2024, drawing the initial $25.0 million tranche. This resulted in a significant increase in interest expense ($3.1 million) compared to the prior year.
- Non-Cash Items: The company recorded a $11.2 million gain from the change in fair value of the contingent earnout liability, partially offsetting operating losses.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With $8.5 million in cash, existing resources are insufficient to fund operations for the next 12 months without additional financing.
- Capital Needs: The company expects to require substantial additional capital to fund clinical trials for nelitolimod and commercialization of TriNav. It has a Standby Equity Purchase Agreement (SEPA) allowing for up to $30.0 million in equity sales and a credit facility with potential additional draws contingent on revenue targets.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including insufficient trained resources for complex accounting, inadequate controls over the business combination, and valuation of derivative liabilities. A remediation plan is underway.
- Reimbursement: TriNav received a permanent HCPCS code (C9797) effective January 2024 and a second code (C8004) effective April 2025 for mapping procedures, providing reimbursement clarity.
- Clinical Development: Nelitolimod is in Phase 1/1b trials for uveal melanoma, liver cancer, and pancreatic cancer. Data for the pancreatic cancer trial (PERIO-03) is anticipated in 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any new equity or debt financing required to address the "substantial doubt" regarding going concern status.
- Debt Covenants: Monitor compliance with the OrbiMed Credit Agreement, specifically the minimum cash balance requirement (increasing to $10.0 million after March 31, 2025) and revenue thresholds required to access the remaining $25.0 million in delayed draw commitments.
- Internal Control Remediation: Track the progress of remediation efforts for the identified material weaknesses in financial reporting and internal controls.
- Reimbursement Stability: Confirm that the new permanent HCPCS codes for TriNav are being successfully utilized by hospitals and that reimbursement rates remain stable.
- Clinical Milestones: Monitor the enrollment and data readout timelines for the nelitolimod Phase 1 trials, particularly the PERIO-03 pancreatic cancer study.